United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Joii Multiwormer 230 mg/20 mg Film-coated Tablets for Cats
Krka Multiwormer 230 mg/20 mg Film-coated Tablets for Cats

Date Created: September 2021

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Joii Multiwormer 230 mg/20 mg Film-coated Tablets for Cats Krka Multiwormer 230 mg/20 mg Film-coated Tablets for Cats
Applicant	KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia
Active substance	Pyrantel embonate, praziquantel
ATC Vetcode	QP52AA51
Target species	Cats
Indication for use	For the treatment of mixed infestations with roundworms, hookworms and tapeworms in cats, caused by: - adult stages of ascarids: *Toxocara cati (syn. mystax)* - adult stages of hookworms: *Ancylostoma tubaeforme, Ancylostoma braziliense* - -tapeworms*: Echinococcus multilocularis, Dipylidium caninum, Hydatigera (Taenia) taeniaeformis, Mesocestoides spp., Joyeuxiella pasqualei.*

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	July 2021

I. SCIENTIFIC OVERVIEW

These applications were submitted in accordance with Article 13(1) of Directive 2001/82/EC as amended. The reference product was Drontal 230/20 mg Filmtabletten zum Eingeben fur Katzen, first authorised in Germany in 1995. The products are indicated for use in cats, for the treatment of mixed infestations with roundworms, hookworms and tapeworms, caused by adult stages of ascarids: *Toxocara cati (syn. Mystax),* adult stages of hookworms: *Ancylostoma tubaeforme, Ancylostoma braziliense,* tapeworms*: Echinococcus multilocularis, Dipylidium caninum, Hydatigera (Taenia) taeniaeformis, Mesocestoides spp.,* and *Joyeuxiella pasqualei.* The dose rate is 5 mg praziquantel and 20 mg pyrantel base (57.5 mg pyrantel embonate) per kg of body weight. This corresponds to 1 tablet per 4 kg of body weight. Kittens weighing less than 1 kg should not be treated with the product, because correct dosing of such cats may not be feasible.

The products are produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the products can be safely used in the target species, any reactions observed are indicated in the SPC.[1] The products are safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy [2] of the products was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

[1] SPC – Summary of product Characteristics.
[2] Efficacy – The production of a desired or intended result.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

Per tablet, the products contain 230 mg pyrantel embonate, (equivalent to 80 mg pyrantel), and 20 mg praziquantel. The excipients are maize starch, povidone K25, cellulose microcrystalline (E460), silica colloidal anhydrous, magnesium stearate (E572), hypromellose, macrogol 4000 and titanium dioxide.

The container/closure system consists of blister packs made of cold formed OPA/Aluminium/PVC foil and aluminium foil in a box. The box contains a blister with two tablets . The particulars of the containers and controls performed are provided and conform to the regulation.
The choice of the formulation and the absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of a wet granulation of the ingredients, followed by film-coating.

Process validation data on the product have been presented in accordance with the relevant guidelines.

II.C. Control of Starting Materials

The active substances are pyrantel embonate and praziquantel, established active substances described in the European Pharmacopoeia. The active substances are manufactured in accordance with the principles of good manufacturing practice.

The active substance specifications are considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with specifications have been provided. Acceptable certificates of suitability were provided. Excipients and packaging are suitably controlled with regard to quality.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, uniformity of dose and mass, identification, content of active substances and related substances, dissolution of active substances and microbiological quality.

II.F. Stability

Stability data on the active substances have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life of halved tablets after first opening the immediate packaging: 1 month.
Store unused parts of the halved tablets below 25°C. Each time an unused part-tablet is stored until next use, it should be returned to the open blister pocket and kept in a safe place out of the sight and reach of children.

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

III.A Safety Documentation

Due to the nature of the applications, no additional toxicological and pharmacological data were required.

User Safety

A user risk assessment was provided in compliance with the relevant guideline.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following user recommendations are appropriate:

In case of accidental ingestion, seek medical advice and show the package leaflet to the physician.
Part tablets should be returned to the open blister, and replaced in the cardboard box to be used at the next administration.
In the interest of good hygiene, persons administering the tablets directly to the cat or by adding them to the cat's food, should wash their hands afterwards.

Other precautions

Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

IV. CLINICAL DOCUMENTATION

IV.I. Pre-Clinical and IV.II Clinical Studies

Pharmacology

A comparative dissolution study on both pyrantel and praziquantel was provided, (as bioequivalence could not be examined for pyrantel due to poor absorption of this active substance), which gave satisfactory results, establishing that the proposed products are essentially similar to the reference product. For pharmacokinetic parameters, an *in vivo* bioequivalence study was performed for praziquantel.

Tolerance in the Target Species

Tolerance studies were not required because the proposed products were shown to be essentially similar to the reference product.

Resistance

Suitable references were provided. Adequate warnings and precautions appear on the product literature.

Dose confirmation studies

A dose confirmation study on the products provided satisfactory results. Taken together, despite there being slight differences in the excipients in the proposed and reference products, all results satisfactorily demonstrated that the products are comparable to the reference product, with regard to efficacy.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the products are used in accordance with the Summary of Product Characteristics the benefit/risk profile of the products is favourable.

MODULE 4

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)